Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;61(8):2295-2306.
doi: 10.1111/trf.16573. Epub 2021 Jul 8.

COVID-19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes

Ana Paula H Yokoyama  1 , Silvano Wendel  2 , Carolina Bonet-Bub  1 , Roberta M Fachini  2 , Ana Paula F Dametto  1 , Fernando Blumm  3 , Valeria F Dutra  1 , Gabriela T P Candelaria  2 , Araci M Sakashita  1 , Rafael Rahal Guaragna Machado  4 , Rita Fontão-Wendel  2 , Nelson Hamerschlak  1 , Ruth Achkar  2 , Murillo Santucci Cesar Assunção  1 , Patrícia Scuracchio  2 , Victor Nudelman  1 , Laerte Pastore  5 , João R R Pinho  1 , Mirian Dal Ben  5 , Roberto Kalil Filho  5   6 , Alexandre R Marra  1   7 , Mariane T Amano  5 , Esper G Kallás  5   8 , Alfredo Salim Helito  5 , Carlos Roberto Ribeiro de Carvalho  5   9 , Danielle Bastos Araujo  4 , Edison Luiz Durigon  4   10 , Anamaria A Camargo  5 , Luiz V Rizzo  1 , Luiz F L Reis  5 , Jose M Kutner  1
Affiliations

COVID-19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes

Ana Paula H Yokoyama et al. Transfusion. 2021 Aug.

Abstract

Background: Current evidence regarding COVID-19 convalescent plasma (CCP) transfusion practices is limited and heterogeneous. We aimed to determine the impact of the use of CCP transfusion in patients with previous circulating neutralizing antibodies (nAbs) in COVID-19.

Methods: Prospective cohort including 102 patients with COVID-19 transfused with ABO compatible CCP on days 0-2 after enrollment. Clinical status of patients was assessed using the adapted World Health Organization (WHO) ordinal scale on days 0, 5, and 14. The nAbs titration was performed using the cytopathic effect-based virus neutralization test with SARS-CoV-2 (GenBank MT126808.1). The primary outcome was clinical improvement on day 14, defined as a reduction of at least two points on the adapted WHO ordinal scale. Secondary outcomes were the number of intensive care unit (ICU)-free days and the number of invasive mechanical ventilation-free days.

Results: Both nAbs of CCP units transfused (p < 0.001) and nAbs of patients before CCP transfusions (p = 0.028) were associated with clinical improvements by day 14. No significant associations between nAbs of patients or CCP units transfused were observed in the number of ICU or mechanical ventilation-free days. Administration of CCP units after 10 days of symptom onset resulted in a decrease in ICU-free days (p < 0.001) and mechanical ventilation-free days (p < 0.001).

Conclusion: Transfusion of high titer nAbs CCP units may be a determinant in clinical strategies against COVID-19. We consider these data as useful parameters to guide future CCP transfusion practices.

Keywords: COVID-19; SARS-CoV-2; convalescent plasma transfusion; neutralizing antibodies.

PubMed Disclaimer

Conflict of interest statement

The authors have disclosed no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Timeline of COVID‐19 patients included in the study [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2
FIGURE 2
Clinical improvement on day 14 post‐CCP transfusion. nAbs P0 = Neutralizing antibody titers from patient samples before convalescent plasma transfusion, nAbs CP = mean geometric titer of nAbs from CP units transfused. Variables without a p value mean that p was not statistically significant
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life‐threatening COVID‐19: a randomized clinical trial. JAMA. 2020;324:460–470. 10.1001/jama.2020.10044 Erratum in: JAMA. 2020;324(5):519. PMID: 32492084; PMCID: PMC7270883. - DOI - PMC - PubMed
    1. Liu STH, Lin H‐M, Baine I, et al. Convalescent plasma treatment of severe COVID‐19: a propensity score‐matched control study. Nat Med. 2020;26:1708‐1713. 10.1038/s41591-020-1088-9 - DOI - PubMed
    1. Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID‐19 convalescent plasma in 5000 patients. J Clin Invest. 2020;2020:140200. 10.1172/JCI140200. - DOI - PMC - PubMed
    1. Cao B, Wang Y, Wen D, et al. A trial of Lopinavir‐ritonavir in adults hospitalized with severe Covid‐19. N Engl J Med. 2020;382:1787–1799. 10.1056/NEJMoa2001282. - DOI - PMC - PubMed
    1. Beigel JH, Tomashek KM, Dodd LE, et al. ACTT‐1 study group members. Remdesivir for the treatment of Covid‐19 ‐ final report. N Engl J Med. 2020;383:1813–1826. 10.1056/NEJMoa2007764. - DOI - PMC - PubMed

Publication types